Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to potentially improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition, according the company’s website (see here: http://immunepharmaceuticals.com/). SNNLive caught up with Dr. Daniel Teper, CEO of Immune Pharmaceuticals, Inc. at the Marcum MicroCap Conference on May 28th, 2015 in New York City, NY.
“Immune Pharmaceuticals, as our name exemplifies, is all about immunology and targeted therapy for autoimmune diseases and cancer. We started 4 years ago in Israel, and we are now listed on NASDAQ and headquartered in New York City at the Alexandria Center for Life Science. In fact, last Tuesday, we celebrated those two events by ringing the bell at NASDAQ,” Dr. Teper begins.
Dr. Teper continues by discussing the science behind the company’s therapeutics that they are currently in clinical development, as well as an update on their clinical trials, the size of the Crohn’s and colitis markets, the company’s neuropathic pain drug that Immune Pharmaceuticals is working on partnering for, and insight into where the company is headed for 2015-16.
For more information about Immune Pharmaceuticals, go to: www.ImmunePharmaceuticals.com
© 2017 Stock News Now
Supported by Superior Web Solutions